Ignis Therapeutics
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A biotech developing innovative biologic therapies for major ophthalmic diseases.
Ophthalmology
Technology Platform
A platform for engineering and optimizing biologic therapies, specifically antibodies and proteins, for targeted delivery and sustained action in ocular tissues.
Opportunities
Large and growing patient population in China and globally with age-related retinal diseases creates a significant market for improved therapies.
Risk Factors
High clinical development risk in ophthalmology and potential challenges in differentiating from entrenched, highly effective standard-of-care biologics.
Competitive Landscape
Faces intense competition from global giants like Roche/Genentech and Regeneron in the wet AMD space, as well as other biotechs developing longer-acting anti-VEGF and novel pathway inhibitors.